“I once met a patient with a heart disease who needed surgery through a robot. But even if I promised to help her operate for free, she still gave up because she couldn’t afford other expenses… ” Dr. Sudhir, the founder of Hangzhou surgical robot, told arteria network that it was this experience that made him determined to develop a surgical robot that ordinary people can afford.
Dr. Sudhir gave up his status as a robotic heart surgeon in the United States and an assistant professor at the University of Chicago, and came to China with all his savings to develop surgical robots. Dr. Sudhir told arteria network that he wanted to help more people, and China not only needed such a technology, but also the capital side gave him financial support.
To build a local brand of Chinese surgical robot, the advantage of “price + technology” boosts the product landing
Looking back on the development history of surgical robot, Da Vinci series can be regarded as the pioneer in this field. In 2000, Da Vinci surgical robot came out, monopolized related patents for 20 years, and almost dominated the market. The emergence of Da Vinci surgical robot has improved the common problems in traditional surgery, such as poor accuracy, long operation time and lack of three-dimensional precision vision. However, due to the high cost of equipment purchase, many medical systems in developing countries and backward areas are unable to popularize this system. In China, the purchase price of the system is as high as 20 million yuan. The high price has become the biggest obstacle for the series of surgical robots to be widely used in the medical field.
With the concept of more intelligent system, more human-oriented operation and more controllable cost, Hangzhou shuchuang focuses on the research and development of a new generation of therapeutic surgical robots, making them more suitable for the market and soil of developing countries with more people-friendly purchase cost.
At present, cadaver has been developed to the third generation system and has been tested in India. Dr. Sudhir, founder of Hangzhou surgery, told arteria network that cadaver is expected to conduct clinical trials in India within two months, and then promote the process of conducting clinical trials in multi centers around the world.
The robot is priced at $600000, about a third of the price of Da Vinci’s surgical robot. In addition to the advantage in price, in the system, the surgical robot can be modularized split and assembled, and the doctor can place the mechanical arm around the patient according to the treatment demand, and realize accurate treatment based on the independent program of each mechanical arm. The free adjustment and combination of the manipulator, as well as the constantly updated modular components in the research and development, make the application of surgical robot mainly for heart surgery expand to urology, general surgery, thoracic surgery, gynecology, head and neck surgery and other fields.
In terms of operation and application, Hangzhou shuchuang improved the design of surgical robot system in line with ergonomics. In the use of traditional surgical robot, doctors need to keep their body forward and watch the endoscopic images through an 8-inch screen, which is easy to bring discomfort to doctors and lead to errors in the operation process. The surgical robot provides a panoramic open system, which provides a more humanized operation mode for doctors. Not only can the doctor see his hands and feet, but also during the operation, the doctor does not need to keep leaning forward, and only needs to lean back on the operating chair.
Due to the improvement of the operating system, its monitor has also been upgraded to an open large screen (about 26 inches). A 26 inch screen means not only higher resolution and larger images, but also higher magnification and accuracy. This is what da Vinci’s surgical robot system can’t achieve.
The display presents the endoscopic image to the chief surgeon in a panoramic way, so that the operation team can have the same three-dimensional observation field as the chief surgeon, making the operation process more efficient and safe. At the same time, the design will also help students to learn the operation process. Based on this, Hangzhou shuchuang has established relevant training mode to improve the learning efficiency of surgical robot, that is, video card is implanted in the system to provide recording and playback functions, and help doctors communicate, guide and learn remotely.
The surgical robot also has an intelligent safety system, which is equipped with eye movement tracker based on magnetic sensor to monitor the collision situation, so as to avoid collision.
“In fact, there is another difference between our robot and the Da Vinci system, which is that the surgical robot can perform remote control through computer assistance.” Dr. Sudhir told arteria network, “because the Da Vinci system has not yet made changes to the core technology developed in the late 1990s, it has never been able to make a breakthrough in technology.”
With the advent of 5g and optical fiber network, the surgical robot system is developing the technology of remote guidance for surgeons at any time and in real time. This remote technology enables more people to discuss and study surgical treatment, and greatly reduces the learning cost of medical staff for machine and surgical treatment. On the other hand, Hangzhou shuchuang plans to set up Omni studio, an operation team based on remote guidance.
In the future, with the further development of technology, doctors will be able to carry out remote surgery through the surgical robot platform, break through the limitation of region and time, realize the sharing of doctor resources, and make medical achievements truly enjoyed by more people.
Hangzhou shuchuang holds 142 patents, and continues to apply for new patents, establishing its professional barriers in the research and development of surgical robots, so as to achieve more innovative breakthroughs in the research and development of surgical robots.
With China as the core to link the world, the team gathered experts in the field of cardiac surgery from all over the world
Dr. Sudhir adheres to the original intention of making this technology benefit more people, and chooses China, which has lower production price, higher productivity and relevant medical policy support in technology research and development, as the research and development soil of surgical robot, to establish a parent company, reduce the price of surgical robot and implement the project. At the same time, Hangzhou shuchuang will link its industrial chain to the world, establish medical technology research, manufacturing and assembly companies in India, and establish equipment R & D and innovation companies in the United States to provide more possibilities for the R & D of surgical robots.
Aiming at the goal of “benefiting more people”, Hangzhou shuchuang not only reduces the output of R & D and manufacturing funds through production layout, but also reduces the production price of products. At the same time, the installment plan is put forward to help the buyers with insufficient funds enjoy the equipment and reduce the burden of full payment.
Behind the enterprise development is the support of the company team. Dr. Sudhir Srivastava, the founder of Hangzhou shuchuang, is one of the most important global experts in the field of robotic cardiac surgery. He has accumulated more than 45 years of clinical practice experience and has rich research and practice in the international leading robotic cardiac surgery technology. So far, Dr. Sudhir has operated more than 1400 Da Vinci robot cardiothoracic surgeries, worked in PLA 301 in Beijing and Ruijin Hospital in Shanghai, and implemented medical plans in Chicago, Atlanta, India and other countries. Dr. Sudhir is also an active member of the society of thoracic surgeons, the international society for minimally invasive cardiothoracic surgery (ismics) and the society for robotic revascularization.
Dr. Sudhir’s training experience in hundreds of teams around the world, as well as his teaching experience in the University of Chicago, has driven him to practice for the company to include more young people, and to provide meaningful teaching support for all students who want to learn minimally invasive technology.
At the same time, the Hangzhou surgical team is composed of multinational personnel from China, the United States, India, New Zealand and other places, with 15 to 30 years of experience in the field of cardiac surgery. For example, Dr. valluvan jeevanandam, a high-risk heart surgery expert and member of the board of directors of Hangzhou surgery, specializes in the surgical treatment of heart failure. Dr. valluvan jeevanandam, who has performed more than 1000 heart transplantation, artificial heart surgery and cardiac surgery, is a recognized leader in the field of advanced heart failure, and has innovated and developed long-term intra aortic balloon assisted devices.
Hangzhou shuchuang surgical robot Co., Ltd. was established in 2016 with a US $5 million investment in Hangzhou. In May 2017, it was invested by daotong investment with us $1.5 million in round a financing. In October 2017, it was invested by Shanghai New Silk Road Financial Holding Co., Ltd. and invested by India Medical Fund in a + round of US $5 million. In October 2018, it was led by Taiheng investment, followed by Heda investment and thunderstorm capital in round B financing. In December 2019, it won the B + round of financing led by sinopharm-cicc medical industry fund, followed by Zheshang venture capital and new Silk Road financial holdings.
Financing history of Hangzhou shuchuang
Next, Hangzhou shuchuang will raise $100 million to make final preparations for going public.
The blue ocean era of surgical robot market has come
“I think the blue ocean era of the surgical robot market has arrived.” Dr. Sudhir said.
As the Research Report of China Business Industry Research Institute shows, surgical robot, as an emerging industry, will usher in a golden age driven by national policy support, aging, medical services in short supply and other factors.
Hangzhou shuchuang’s success in financing and the penetration of its products in the Asia Pacific region by virtue of its own advantages also show a huge market opportunity for its surgical robot system.
Hangzhou Zhuchuang adopts the business model of direct selling and distribution to sell its products. At present, Hangzhou shuchuang has established cooperative relations with Indian and Chinese hospitals, and received 85 letters of intent from Indian hospitals. Hangzhou shuchuang will select ten hospitals around the world to conduct global multi center clinical trials to speed up the implementation of its products.
At the same time, with the breakthrough and integrated development of mobile Internet, big data, cloud computing, Internet of things, artificial intelligence and other information technologies, the digital economy has developed rapidly. As the representative of hard science and technology, the robot industry will make use of the technological dividend in the digital economy to accelerate the development of robots.
Surgical robot, the inevitable trend of medical robot industry in the future
According to daotong capital’s observation on the surgical robot industry, the arterial network sorted out the following core views:
1. The development of medical robot industry is an inevitable trend. Under the background of global aging population and serious shortage of medical staff in the future, intelligent medical robot will become the most important solution to solve the imbalance between supply and demand. In the past four years, China’s medical robot market has grown more than 10 times.
2. The medical robot market is the second largest robot market in the world, and the surgical robot market accounts for the largest share in the medical robot market. Surgical robot is the next generation of surgical operation. With the progress of technology, the learning curve of surgeons will be shorter, the surgical results will be more standardized, and the trauma of patients will be smaller, and the postoperative healing time will be shorter.
3. The mode of surgical robot equipment + consumables + service can form a closed-loop business, in which consumables will account for more than 50% of the market share of surgical robot.
4. From the technical level: surgical robot has entered the stage of natural cavity, including vascular intervention, bronchoscope surgical robot, and can be extended to urethra and anus in the future; from the product form: miniaturization and specialization are the development trend of surgical robot.
5. For surgical robot enterprises, the development of equipment is only the first step of the long march. From supporting consumables, laws and patents, training, to the accumulation of clinical cases, a good robot company also needs to constantly establish an ecology around its equipment.
At present, the domestic surgical robot has been on the air. With the expiration of the 20-year patent of Da Vinci surgical robot, the domestic surgical robot is expected to overtake in the curve.
Editor in charge: PJ